Foundayo vs Ozempic: which Ozempic, and what actually differs

Before you read. This guide is educational and does not replace your Medication Guide, pharmacist, prescriber, diagnosis, or emergency care. Both medicines are prescription-only. Nothing here recommends one over the other, tells you to start, stop, or change a dose, or overrides an instruction your own prescriber gave you. If anything here differs from what your care team said, their instruction wins.

Quick answer

Before anything else: Ozempic is now two different products. There is the once-weekly injection it has meant since 2017, and there is a once-daily Ozempic tablet, which shares a prescribing label with Rybelsus. They are not interchangeable, and almost every "Foundayo vs Ozempic" comparison online silently assumes the injection.

What both forms of Ozempic have in common: in the United States they are approved for type 2 diabetes, not for weight loss.

Foundayo is orforglipron from Eli Lilly, a once-daily tablet approved on 1 April 2026 for adults with obesity, or adults with overweight who have at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity.

So the short version: Foundayo is a weight-management medicine, and Ozempic in either form is a diabetes medicine. If you came here comparing two weight-loss drugs, the labels do not support that framing, and the next section explains what you probably meant instead.

Track a daily tablet in Takely →

Ozempic is now two products

This is the part that makes most of the advice on this topic wrong, so it goes first.

Ozempic injection is subcutaneous semaglutide, given once weekly. Its label carries three indications: improving glycemic control in adults with type 2 diabetes, reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

Ozempic tablets are oral semaglutide, taken once daily in 1.5 mg, 4 mg and 9 mg strengths. They share a prescribing label with Rybelsus, and that label is explicit about the relationship: RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis. The shared tablet label carries two indications, not three: glycemic control in adults with type 2 diabetes, and reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events.

The tablet also inherits oral semaglutide's whole rulebook. One tablet orally once daily on an empty stomach in the morning with water, up to 4 ounces; no other liquids; swallow whole, do not split, crush, chew or dissolve; then wait at least 30 minutes before food, other beverages, or other oral medicines. If a dose is missed, skip it and take the next one the following day.

We walk through what that morning actually looks like in the Ozempic tablet morning routine.

So when someone asks whether Foundayo is better than Ozempic, the first question back is: the pen, or the tablet? They ask completely different things of a day.

The comparison most people mean is not this one

Ozempic became shorthand for GLP-1 medicine generally, which is how "Foundayo vs Ozempic" gets typed by people who are not asking about type 2 diabetes at all.

If your actual question is pill or injection, for weight management, the label-supported comparison is Foundayo versus Wegovy — Wegovy is the semaglutide brand carrying the weight-management indication, and it exists as both a pen and a tablet. The Wegovy pill and pen compared covers that pairing directly.

If your question is which daily GLP-1 tablet, the comparison is Foundayo compared with Rybelsus — and everything said there about Rybelsus applies to Ozempic tablets too, since they share a label.

None of this is pedantry about brand names. Indication determines which prescriber conversation you are having, which formulary tier the drug sits in, and whether your insurance treats the prescription as covered or excluded. Getting the comparison right is the difference between a useful appointment and a confusing one.

What each is approved for in the US

	Foundayo (orforglipron)	Ozempic tablets	Ozempic injection
Maker	Eli Lilly	Novo Nordisk	Novo Nordisk
Form	Tablet	Tablet	Subcutaneous injection, pen
Frequency	Once daily	Once daily	Once weekly
Approved for weight management	Yes	No	No
Approved for type 2 diabetes	No	Yes	Yes
Cardiovascular indication	No	Yes, at high CV risk	Yes, with established CV disease
Kidney indication	No	No	Yes, with chronic kidney disease
Molecule	Small molecule, non-peptide	Peptide, with SNAC	Peptide
Empty stomach required	No	Yes	No
Refrigeration	No	No	Yes, before first use
Boxed warning	Thyroid C-cell tumors	Thyroid C-cell tumors	Thyroid C-cell tumors

Two rows tend to surprise people. Neither Ozempic product carries a weight-management indication in the US, so prescribing either one for weight is an off-label decision a clinician makes case by case. And the Ozempic tablet is the only column here with an empty-stomach rule — the injection has none, and neither does Foundayo.

Two molecules, three delivery problems

Both drugs activate the same receptor. Getting there is where they diverge.

Semaglutide is a peptide, and peptides do not survive a stomach intact. Injecting it sidesteps the problem entirely, which is why the pen has no food rule at all. Making it swallowable takes an absorption enhancer, salcaprozate sodium or SNAC, which works in a narrow window against the stomach lining — and that window is what the empty stomach, the 4-ounce limit and the 30-minute wait exist to protect. Same molecule, two delivery systems, two completely different sets of daily constraints.

Orforglipron is a small molecule and not a peptide at all. It survives digestion without help, which is why its label attaches no fasting rule, no water limit, and no time-of-day restriction: take Foundayo orally once daily, with or without food. Swallow tablets whole. Do not break, crush, or chew. What Foundayo is and how the molecule works goes through that chemistry properly.

Read the three together and the pattern is clean. The injection buys freedom about food and charges a needle and a fridge. The oral peptide buys "no needle" and charges a protected half hour every morning. The small molecule is the only one that charges neither — and asks instead that you remember it 365 times a year.

The dosing ladders, side by side

All three climb slowly. They climb on different clocks.

Foundayo has six strengths — 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg — and holds each for at least 30 days. The first three steps are written as scheduled increases; 9 mg, 14.5 mg and 17.2 mg are increases that may be made based on treatment response and tolerability. The maximum is 17.2 mg once daily. The full Foundayo dosage chart sets out every step.

Ozempic tablets start at 1.5 mg once daily for days 1 to 30, a dose the label states is not effective for glycemic control. Days 31 to 60 go to 4 mg. On day 61 or later the label gives a fork: if no additional glycemic control is needed, stay at 4 mg; if it is, increase to 9 mg.

Ozempic injection starts at 0.25 mg once weekly, moves to 0.5 mg after 4 weeks, then may go to 1 mg after at least 4 weeks on 0.5 mg, and to 2 mg after at least 4 more.

	Foundayo	Ozempic tablets	Ozempic injection
Doses	0.8, 2.5, 5.5, 9, 14.5, 17.2 mg	1.5, 4, 9 mg	0.25, 0.5, 1, 2 mg
Rhythm	Once daily, any time	Once daily, morning only	Once weekly, same day each week
Minimum per step	30 days	30 days	4 weeks
Steps to maximum	Five	Two	Three
Starting dose therapeutic?	Part of the ladder	No — label says not effective for glycemic control	No — an initiation dose
Missed dose	Skip; see your Medication Guide	Skip it, take the next one the following day	Give as soon as possible within 5 days

That last row is the real difference in daily life. A weekly injection has a five-day recovery window written into its label. A daily tablet has none — a skipped day is simply a skipped day, and the tablet label caps you at one per day regardless.

Daily and weekly medicines fail in opposite ways, and both failures are invisible by the next appointment. Takely records what you took and when, next to a one-line note on how the day went, so the pattern is on a timeline instead of in memory. Open Takely in your browser →

Do the side effects differ?

Same family, same boxed warning, same dominant category.

All three carry the thyroid C-cell tumor boxed warning derived from rodent studies, and all three are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. The tablet label states plainly that it is unknown whether these products cause thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.

Foundayo's warnings and precautions list nine items: risk of thyroid C-cell tumors, acute pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, hypoglycemia, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation. The semaglutide tablet label carries the same nine headings.

The most common adverse reactions on Foundayo, as the label prints them, are led by nausea at 26% on 5.5 mg, 34% on 9 mg and 35% on 17.2 mg, against 10% on placebo. Constipation, diarrhea and vomiting follow the same dose-related shape.

One category applies only to the injection: injection-site reactions. One applies only to the tablets: the swallowing rule, and for oral semaglutide, everything the 30-minute window governs.

Why the side-effect tables cannot be lined up

We are not going to put Foundayo's percentages next to semaglutide's, and the reason is not caution for its own sake.

Foundayo's adverse-reaction numbers come from an obesity trial program. Semaglutide's tablet numbers come from type 2 diabetes trials — the larger pooled analysis covers 4,116 patients with type 2 diabetes across nine placebo- and active-controlled trials, mean exposure 59.8 weeks. Different populations, different baseline health, different concomitant medications, different follow-up.

Setting two such numbers side by side and declaring a winner is a cross-trial comparison. It looks quantitative and supports no conclusion about either drug relative to the other. Only a head-to-head trial does that.

What the tables do tell you is the shape of the experience: gastrointestinal reactions dominate, they are dose-related, and they concentrate during escalation. That holds across this entire drug class.

Fridge, needles, and what travel looks like

Here the split is not Foundayo versus Ozempic. It is injection versus tablet, and Ozempic sits on both sides of it.

Ozempic pens are stored in the refrigerator at 2–8 °C before first use. After first use a pen may be kept refrigerated or at room temperature not exceeding 30 °C, for up to 56 days. The label also says not to freeze it and not to use it if it has been frozen. Practically: a cold chain to plan around, plus sharps disposal.

Foundayo and Ozempic tablets are both bottles of tablets. No refrigeration, no needles, no sharps. What the Ozempic tablet costs you instead is the morning — the empty stomach and the 30-minute wait travel with you, and they are harder to protect in a hotel, on a flight, or in someone else's kitchen than they are at home.

Against all that, the pen is once weekly and can be taken at any time of day with or without meals, and its administration day can move as long as more than 48 hours separate two doses.

Neither trade is universally better. They are different failure modes: a weekly injection is easy to remember and awkward to travel with; a daily tablet is easy to travel with and easy to forget. Takely was built for the second kind — it will track a daily tablet without injection-shaped fields getting in the way.

Cost and coverage

Different indications usually mean different coverage rules, and that is the practical consequence of everything above.

A type 2 diabetes medicine and a weight-management medicine sit in different formulary tiers on most US plans, and plenty of plans that cover the first exclude the second outright. A list price tells you almost nothing about your own number, which is set by your plan, your tier, and whether a manufacturer savings program applies to you.

Because those figures move month to month, the only reliable answer comes from your plan's formulary and your pharmacist rather than from any page on the internet, including this one.

Frequently asked questions

Is Foundayo the same as Ozempic?

No. They are different molecules from different companies with different US approvals. Foundayo is orforglipron, a small-molecule tablet approved for weight management. Ozempic is semaglutide, a peptide sold as both a once-weekly injection and a once-daily tablet, approved for type 2 diabetes and cardiovascular risk reduction.

Is Ozempic approved for weight loss?

Not in the US, in either form. The injection's indications cover glycemic control, cardiovascular risk in established CV disease, and kidney outcomes in chronic kidney disease, all in type 2 diabetes. The tablet's cover glycemic control and cardiovascular risk. The semaglutide brand carrying a weight-management indication is Wegovy.

Is there an Ozempic pill?

Yes. Ozempic tablets are oral semaglutide in 1.5 mg, 4 mg and 9 mg, taken once daily, sharing a prescribing label with Rybelsus. The label states the two are not substitutable on a mg-to-mg basis, so they are not the same prescription written two ways.

Does Foundayo need to be taken on an empty stomach like the Ozempic pill?

No, and this is the clearest practical difference between them. Foundayo's label says once daily with or without food, with no water limit and no waiting period. Ozempic tablets require an empty stomach in the morning, up to 4 ounces of plain water, and at least a 30-minute wait before food, other drinks, or other oral medicines.

Can Foundayo replace Ozempic?

That is a prescribing decision, not a swap you can make yourself. The two hold different indications, so for someone taking Ozempic for type 2 diabetes they are not equivalent products. Both labels also state that concomitant use with another GLP-1 receptor agonist is not recommended.

Which has worse side effects?

The labels report from different trial programs in different populations, so the percentages are not comparable. All carry the same boxed warning, all list gastrointestinal reactions as the most common category, and all are dose-related. Your own risk profile is a question for your prescriber.

Primary sources and further reading

Labels are revised. Everything on this page was checked against the sources above on 30 August 2026. Check the current label and ask your clinician or pharmacist about your own prescription.